Functional and Molecular Defects of Pancreatic Islets in Human Type 2 Diabetes
- Silvia Del Guerra,
- Roberto Lupi,
- Lorella Marselli,
- Matilde Masini,
- Marco Bugliani,
- Simone Sbrana,
- Scilla Torri,
- Maria Pollera,
- Ugo Boggi,
- Franco Mosca,
- Stefano Del Prato and
- Piero Marchetti
- From the Department of Endocrinology and Metabolism, Metabolic Unit, Cisanello Hospital, Pisa, Italy
- Address correspondence and reprint requests to Piero Marchetti MD, Department of Endocrinology and Metabolism, Metabolic Unit, Ospedale Cisanello, Via Paradisa 2, 56124 Pisa, Italy. E-mail marchant{at}immr.med.unipi.it
Abstract
To shed further light on the primary alterations of insulin secretion in type 2 diabetes and the possible mechanisms involved, we studied several functional and molecular properties of islets isolated from the pancreata of 13 type 2 diabetic and 13 matched nondiabetic cadaveric organ donors. Glucose-stimulated insulin secretion from type 2 diabetic islets was significantly lower than from control islets, whereas arginine- and glibenclamide-stimulated insulin release was less markedly affected. The defects were accompanied by reduced mRNA expression of GLUT1 and -2 and glucokinase and by diminished glucose oxidation. In addition, AMP-activated protein kinase activation was reduced. Furthermore, the expression of insulin was decreased, and that of pancreatic duodenal homeobox-1 (PDX-1) and forkhead box O1 (Foxo-1) was increased. Nitrotyrosine and 8-hydroxy-2′-deoxyguanosine concentrations, markers of oxidative stress, were significantly higher in type 2 diabetic than control islets, and they were correlated with the degree of glucose-stimulated insulin release impairment. Accordingly, 24-h exposure to glutathione significantly improved glucose-stimulated insulin release and decreased nitrotyrosine concentration, with partial recovery of insulin mRNA expression. These results provide direct evidence that the defects of insulin secretion in type 2 diabetic islets are associated with multiple islet cell alterations. Most importantly, the current study shows that the functional impairment of type 2 diabetic islets can be, at least in part, reversible. In this regard, it is suggested that reducing islet cell oxidative stress is a potential target of human type 2 diabetes therapy.
- AMPK, AMP-activated protein kinase
- Foxo-1, forkhead box O1
- GSH, glutathione
- GSSG, GSH disulfide
- KRB, Krebs-Ringer bicarbonate solution
- 8-OHdG, 8-hydroxy-2′-deoxyguanosine
- PDX-1, pancreatic duodenal homeobox-1
Footnotes
-
- Accepted November 30, 2004.
- Received August 19, 2004.
- DIABETES














